|
| Author and year | Sample size | Intervention | Response |
|
Brose et al., 2014 [15]
Phase III DECISION trial | 417 with RAI-refractory DTC. | Sorafenib 400 mg 2x daily. | ORR 12.2% and 0.5%, SD 42% and 33%. |
| Marotta et al., 2013 [16] | 17 with RAI-refractory DTC. | Sorafenib 400 mg 2x daily. | 30% PR, 41% SD. |
| de la Fouchardiere et al., 2013 [17] | 45 with RAI-refractory DTC. | Sorafenib. | 29% PR. |
| Chen et al., 2011 [18] | 9 with RAI-refractory DTC. | Sorafenib 200 mg 2x daily. | 33% PR, 44% SD. |
| Cabanillas et al., 2010 [19] | 13 with RAI-refractory DTC. | Sorafenib 400 mg. | 20% PR, 60% SD, 20% PD. |
| Sherman et al., 2013 [20] | 19 with DTC. | Sorafenib 400 mg 2x daily and everolimus 5 mg daily. | Papillary, 50% PR and 38% SD.
Hurthle cell, 67% PR and 33% SD.
Follicular, 50% PR and 50% SD. |
| Sherman et al., 2012 [21] | 27 with recurrent/refractory DTC, 6 of whom with prior sorafenib. | Sorafenib 200 mg 2x daily with temsirolimus 25 mg weekly. | 38% PR if no prior sorafenib. |
| Hong et al., 2011 [22] | 16 with metastatic DTC. | Sorafenib 400 mg daily with tipifarnib 100 mg 2x daily. | 4.5% PR and 36% SD. |
| Cabanillas et al., 2010 [23] | 22 with metastatic DTC. | Sorafenib with tipifarnib, dose escalation trial. | 7% PR, 86% SD, 7% PD. |
Schlumberger, 2014 [24]
Phase III SELECT trial | 392 with RAI-refractory DTC. | Lenvatinib 24 mg daily. | CR 1.5% and 0%. PR 63.2% and 1.5%. |
| Sherman et al., 2011 [25] | 58 with RAI-refractory DTC. | Lenvatinib 24 mg daily. | PR 50%. |
| Bible et al., 2010 [26] | 37 with RAI-refractory DTC. | Pazopanib 800 mg daily. | 49% PR. |
|
